Who is likely to take over GE Healthcare?

```

There are market reports stating that GE Healthcare is considering selling shares of its China business, and the potential transaction could value the Chinese assets at several billion US dollars.

In response, GE Healthcare (China) told Xin Feng: "We do not comment on market rumors. China is one of the largest healthcare markets in the world, and we are always committed to providing high-quality healthcare services to Chinese patients and customers."

This may have exceeded market expectations.

All along, GE Healthcare has been among the GPS Big Three most deeply engaged with the Chinese market. (GPS Big Three: GE Healthcare, Philips, Siemens Healthineers)

As early as 2023, GE Healthcare (China) announced a strategic upgrade to "full localization, boundless innovation, and win-win cooperation", establishing production bases in cities such as Wuxi, Tianjin, Beijing, Shanghai, and Chengdu, with the Beijing base becoming its largest imaging equipment manufacturing base in the world.

Moreover, over 95% of GE Healthcare's products sold in China are domestically produced. For instance, the supplier of superconducting magnets, the core component of GE Healthcare (China)'s magnetic resonance imaging (MR), is Ningbo Jianxin Superconductor Technology Co., Ltd.

However, due to a slowdown in procurement execution and the rise of domestic manufacturers such as United Imaging Healthcare (688271.SH) and Wandong Medical (600055.SH), GE Healthcare (China) has indeed faced certain challenges.

In the first half of 2025, GE Healthcare's revenue in China was 1.156 billion yuan, a 2% year-on-year decrease, accounting for about 10% of the total.

Recently, GE Healthcare management pointed out at the 23rd Morgan Stanley Global Healthcare Conference: "The era of 10% growth in the Chinese market is over, and future growth will remain in the single digits. As long as the Chinese market remains stable, the company's medium-term goals and strategies are fully achievable."

Xin Feng has verified with several leading domestic medical device companies as to whether they will participate in the sale of GE Healthcare’s China business, and all parties currently say they are not aware of it.

Who will become the next owner of GE Healthcare’s China business remains to be seen.

Risk Warning and DisclaimerThe market has risks, investment needs caution. This article does not constitute personal investment advice, nor does it consider the individual investment objectives, financial situation, or needs of any particular user. Users should consider whether any opinions, views, or conclusions in this article are suitable for their specific situation. Investing accordingly is at your own risk. ```